Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) Debt to Equity: 2010-2022

Historic Debt to Equity for Anika Therapeutics (ANIK) over the last 5 years, with Jun 2022 value amounting to $0.02.

  • Anika Therapeutics' Debt to Equity fell 74.36% to $0.02 in Q2 2022 from the same period last year, while for Jun 2022 it was $0.06, marking a year-over-year decrease of 78.36%. This contributed to the annual value of $0.02 for FY2021, which is 68.72% down from last year.
  • Latest data reveals that Anika Therapeutics reported Debt to Equity of $0.02 as of Q2 2022, which was up 0.22% from $0.02 recorded in Q1 2022.
  • Over the past 5 years, Anika Therapeutics' Debt to Equity peaked at $0.17 during Q2 2020, and registered a low of $0.01 during Q3 2021.
  • For the 3-year period, Anika Therapeutics' Debt to Equity averaged around $0.06, with its median value being $0.05 (2020).
  • Data for Anika Therapeutics' Debt to Equity shows a maximum YoY slumped of 83.24% (in 2022) over the last 5 years.
  • Quarterly analysis of 3 years shows Anika Therapeutics' Debt to Equity stood at $0.05 in 2020, then plummeted by 68.72% to $0.02 in 2021, then slumped by 74.36% to $0.02 in 2022.
  • Its Debt to Equity was $0.02 in Q2 2022, compared to $0.02 in Q1 2022 and $0.02 in Q4 2021.